Birdwatch Note
2025-01-14 16:56:59 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
ASTもALTもおよそ基準範囲内であり、肝障害が疑われるような状況ではありません。 https://www.taisho-kenko.com/special/kenshin-guide/blood02/ アセトアミノフェンを始めとする解熱鎮痛薬は、インフルエンザ等の感染症に伴う発熱や筋肉痛を和らげるのに有効であり、「何のメリットもない」ことはありません。 https://www.ncbi.nlm.nih.gov/pubmed/24261438 https://www.ncbi.nlm.nih.gov/pubmed/26387658
Written by E5771A1EE53EA02C994D22209FAACB38BC0BFB661BDBE513B64C3F69DCDCAFAF
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1878721182465499184
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1879211120906653760
- noteId - 1879211120906653760
- participantId -
- noteAuthorParticipantId - E5771A1EE53EA02C994D22209FAACB38BC0BFB661BDBE513B64C3F69DCDCAFAF
- createdAtMillis - 1736873819935
- tweetId - 1878721182465499184
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 1
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- ASTもALTもおよそ基準範囲内であり、肝障害が疑われるような状況ではありません。 https://www.taisho-kenko.com/special/kenshin-guide/blood02/ アセトアミノフェンを始めとする解熱鎮痛薬は、インフルエンザ等の感染症に伴う発熱や筋肉痛を和らげるのに有効であり、「何のメリットもない」ことはありません。 https://www.ncbi.nlm.nih.gov/pubmed/24261438 https://www.ncbi.nlm.nih.gov/pubmed/26387658
Note Ratings
| rated at | rated by | |
| 2025-01-14 19:42:42 -0600 | Rating Details | |
| 2025-01-14 18:06:30 -0600 | Rating Details | |
| 2025-01-14 17:15:44 -0600 | Rating Details | |
| 2025-01-14 17:10:29 -0600 | Rating Details | |
| 2025-01-14 16:08:45 -0600 | Rating Details | |
| 2025-01-14 15:46:47 -0600 | Rating Details | |
| 2025-01-14 11:45:01 -0600 | Rating Details | |
| 2025-01-14 11:14:07 -0600 | Rating Details | |
| 2025-01-14 23:19:50 -0600 | Rating Details | |
| 2025-01-14 20:14:57 -0600 | Rating Details | |
| 2025-01-14 22:38:36 -0600 | Rating Details | |
| 2025-01-14 22:16:59 -0600 | Rating Details | |
| 2025-01-14 21:18:34 -0600 | Rating Details | |
| 2025-01-14 20:22:29 -0600 | Rating Details | |
| 2025-01-14 18:51:43 -0600 | Rating Details | |
| 2025-01-14 17:59:53 -0600 | Rating Details | |
| 2025-01-14 17:50:43 -0600 | Rating Details | |
| 2025-01-14 17:25:11 -0600 | Rating Details | |
| 2025-01-14 17:14:46 -0600 | Rating Details | |
| 2025-01-14 16:02:34 -0600 | Rating Details | |
| 2025-01-14 15:53:58 -0600 | Rating Details | |
| 2025-01-14 12:39:21 -0600 | Rating Details | |
| 2025-01-14 20:45:30 -0600 | Rating Details | |
| 2025-01-14 17:49:10 -0600 | Rating Details | |
| 2025-01-14 17:03:59 -0600 | Rating Details | |
| 2025-01-14 16:40:07 -0600 | Rating Details | |
| 2025-01-14 16:29:48 -0600 | Rating Details | |
| 2025-01-14 16:19:38 -0600 | Rating Details | |
| 2025-01-14 11:52:37 -0600 | Rating Details | |
| 2025-01-14 11:15:49 -0600 | Rating Details | |
| 2025-01-14 21:44:07 -0600 | Rating Details | |
| 2025-01-14 20:12:23 -0600 | Rating Details | |
| 2025-01-14 17:04:56 -0600 | Rating Details | |
| 2025-01-14 12:59:52 -0600 | Rating Details |